

CancerPACTtm



Cancer Patients' Alliance for Clinical Trials

Listing of Cancer Clinical Trials in the Salinas Valley Fall 2009

Solid Tumors

1. Breast	2
2. Central Nervous System	3
3. Gastrointestinal	4
4. Gynecologic	5
5. Head and Neck	5
6. Lung	6
7. Melanoma	6
8. Prostate	7
9. Urologic	8

Hematologic Cancers

1. Leukemia	8
2. Lymphoma	9
3. Myeloma	10

Other	10
--------------------	----

Program Presented by:

Central Coast Center for Independent Living
Clinica de Salud del Valle de Salinas (CSVs)
Lorenzen Cancer Foundation
Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
Office of Minority Health, Region IX
San Francisco, California, 94103-6706
Phone: 415-437-8124

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Solid Tumors

1. Breast Cancer

1. **40101 Phase III Factorial Randomized Study of Cyclophosphamide and Doxorubicin (CA)(4 vs 6 Cycles) Versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes**
2. CALGB-40302 Phase III Trial of Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
3. **CALGB40503 A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer**
4. CAN-NCIC-MA17 Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor
5. **E1105 Phase III Randomized Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer**
6. E5103 Phase III Double-Blind Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
7. **IBCSG-2402 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)**
8. IBCSG-2502 A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)
9. **N063D ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Phase III Randomized, Multi-centre, Open-label, Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer**
10. NSABP-B-39 Phase III Trial of Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
11. **NSABP-B40 Phase III Randomized Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens**
12. S0221 Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
13. **S0226 Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer**

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

14. S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
15. **S0500 Phase III Randomized Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow Up Assessment**
16. S0230 Phase II Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
17. **NSABP B42 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonged Disease-free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer**
18. NSABP B43 Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-positive Ductal Carcinoma in Situ Resected by Lumpectomy
19. **3144A1-2206 Study Evaluating the Combination of Neratinib and Capecitabine in Solid Tumors and Breast Cancer**
20. PACCT-1 Genomic Profiling for Breast Cancer in Node Negative, ER-Positive and /or PR-Positive Breast Cancer Candidate for Adjuvant Cytotoxic Therapy in Addition to Hormonal Therapy
21. **E2Z04 Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance**

2. Central Nervous System Tumors

1. E3F05 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
2. **N0574 Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases**
3. RTOG 91-10 A PHase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and Oligodendrogliomas
4. **RTOG 0539 Phase II Trial of Observation for Low-risk Meningiomas and of Radiotherapy for Intermediate and High Risk Meningiomas**
5. RTOG 0614 A Randomized Phase III Double-blind Placebo-controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy
6. **RTOG 0825 Phase III Double-blind Placebo-controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma**
7. E1F05 Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
8. **RTOG 0627 Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme**
9. RTOG 0227 Phase I/II Study of Pre-irradiation Chemotherapy with Methotrexate, Rituximab and Temozolomide and Post-irradiation Temozolomide for Primary Central Nervous System Lymphoma

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. **C80405 Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum**
2. E5202 Phase III Randomized Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
3. **E5204 Phase III Intergroup Randomized Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation**
4. N0147 Phase III Randomized Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
5. **NSABPR04 Phase III Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum**
6. S0518 Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patient
7. **S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX**
8. E3204 Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer
9. **E3205 Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma**
10. E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer
11. **E4206 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors**
12. RTOG 0822 A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination with Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

B. Esophageal Cancer

1. **CALGB-80101 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma**
2. **RTOG-0436 A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery**
3. **E2205 A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus**

C. Pancreatic Cancer

4. Gynecologic Cancers

A. Ovarian / Peritoneal Cancer

1. **IBCSG-2402 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)**
2. **MORAb003-003PR An Efficacy and Safety Study of MORAb-003 in First Platinum-Resistant or Refractory Relapsed Ovarian Cancer**

B. Uterine Cancer

1. **GOG0209 Trial of Doxorubicin (Adriamycin)/Cisplatin (Platinol)/Paclitaxel (Taxol)/ G-CSF (Neupogen) vs Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer**

5. Head & Neck Cancer

1. **E1305 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer**
2. **RTOG 0619 A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck**

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

6. Lung

1. **AVF-3991n Phase IV Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) (Monterey Bay Oncology)**
2. 140503 Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
3. **CALGB-30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide**
4. E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
5. **E5597 Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer**
6. N0723 A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
7. **RTOG-0617 A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer**
8. E1508 A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GD-0449 or IGF-IR MoAB IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer
9. **E4508 Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy**
10. RTOG 0618 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-small Cell Lung Cancer
11. **RTOG 0915 A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-small Cell Lung Cancer**
12. RTOG 0813 Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
13. **A7471017 PF-00299804 As a Single Oral Agent In Untreated Adenocarcinoma Of The Lung In Non-Smokers Or Former Light Smokers**
14. S0424 Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men

7. Melanoma

1. **E1697 Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A (microscopic) Melanoma**
2. E1602 Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. **E2602 A Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor**
4. E2607 A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas
5. **S0438 A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirrolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma**

8. Prostate Cancer

1. 90202 Phase III Randomized, Double Blind, Placebo-Controlled Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
2. **C90203 A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer**
3. JPR11 A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer (START) (Limited institution participation)
4. **RTOG 0232 A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma**
5. RTOG 0415 A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable Risk Prostate Cancer
6. **R0521 Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer**
7. RTOG 0534 A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
8. **RTOG 0815 A Phase III Prospective Randomized Trial of Dose-escalated Radiotherapy with or without Short Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer**
9. S0421 Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
10. **SWOG0421 Phase III Trial of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer**
11. RTOG 0526 A Prospective Phase II Trial of Transperineal Untrasound-guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy
12. **RTOG 0621 Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial**
13. RTOG 0622 A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3d-CRT or IMRT Irradiation in High Risk, Clinically Non-metastatic Prostate Cancer after Radical Prostatectomy

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

14. E3805 ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

9. Urologic Cancers (other)

A. Bladder

1. R0524 A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
2. **RTOG 0712 A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant**
3. RTOG 95-06 A Phase I/II Trial of Transurethral Surgery Plus Induction Chemoradiotherapy Followed Either by Selective Bladder Preservation or Radical Cystectomy as Determined by Initial Response and Operability in Patients with Muscle Invading Bladder Cancer

B. Kidney Cancer

1. **E2805 Phase III Sunitinib or Sorafenib in Treating Patients with Kidney Cancer That Was Removed by Surgery**
2. E2804 Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
3. **E4805 Phase II Randomized Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma**

Hematologic Cancers

1. Leukemia

1. CALGB-10501 Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized To Early Intervention Versus Observation with Later Treatment in the High risk Genetic Subset with IGVh Unmutated Disease

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

2. **E2902 Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or Remission after Primary Induction Failure or Patients over Age 60 in First Remission**
3. E2905 Phase III Randomized Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
4. **S0521 Phase III Randomized Trial of Maintenance Versus Observation For Patients With Previously Untreated Low and Intermediate Risk Acute Promyelomic Leukemia (APL)**
5. 10403 Phase II Intergroup Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
6. **10404 Phase II Randomized Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia**
7. E1902 Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes
8. **E1904 Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase, and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)**
9. E1905 Phase II Randomized Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
10. **E1906 Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia(AML)**
11. E2903 Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
12. **S0535 Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia**
13. S0605 Phase II Study of Lenalidomide (Revlimid) (NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
14. **R0524 A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer**
15. E3903 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders

2. Lymphoma

1. **U4391g A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)**

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

2. U2963n An observational Study of Treatment, Outcomes and Prognosis in Patients with Follicular Non-Hodgkins Lymphoma (Monterey Bay Oncology)
3. **CalGB 50303 Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas**
4. E2402 Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
5. **S0816 A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging**

3. Myeloma

1. E1A05 Phase III Randomized Trial of Consolidation Therapy with Bortezomib(Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients with Multiple Myeloma who have Completed a Dexamethasone Based Induction Regimen
2. **E1A06 Phase III Intergroup Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan, Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed Multiple Myeloma Patients who are not Candidates for High Dose Therapy**
3. S0777 Phase III Randomized Trial of CC-5013 (Lenalidomide, NSC-703813 and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
4. **E3A05 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders**

Other

1. AP23573-07-302 Phase III Study of Deforolimus in Treatment of Sarcoma – SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus)
2. **CALGB90601 A Randomized Phase III Study of Gemcitabine, Cisplatin, Bevacizumab or Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma**
3. RTOG 0630 A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org